Major histocompatibility complex class II (MHC II) molecule presenting carrier-protein peptide (MHC II-peptide complex)

Major histocompatibility complex class II (MHC II) molecules presenting carrier-protein peptides are essential immunological complexes that mediate the interaction between antigen-presenting cells (APCs) and CD4+ T cells. These complexes are formed when an MHC II heterodimer (such as HLA-DR, HLA-DQ, or HLA-DP) binds a peptide fragment derived from an exogenous carrier protein, such as CRM197 or Tetanus Toxoid, and displays it on the cell surface [1, 2]. This presentation is the critical signal recognized by T-cell receptors (TCRs), leading to the activation of T-helper cells. In the design of conjugate vaccines, these complexes are the functional targets that allow the immune system to generate high-affinity antibodies against otherwise poorly immunogenic antigens, such as bacterial polysaccharides, by providing necessary T-cell help [3, 4]. Additionally, modern therapeutic strategies leverage these complexes to induce immune tolerance; by presenting specific peptides on MHC II in a non-inflammatory context, drugs like KAN-101 aim to generate regulatory T cells that can suppress autoimmune reactions or anti-drug antibody formation [5, 6]. The effectiveness of these therapies is significantly influenced by the genetic diversity of the MHC II genes, as specific HLA alleles determine the efficiency of peptide binding and subsequent T-cell recognition [1].

Other names

HLA class II-peptide complexMHC-II-restricted antigen complexCarrier-peptide-MHC complexMHC II-CP complex

Activation of CD4+ T-helper cells via TCR recognition of the MHC II-peptide complex, facilitating B-cell help for antibody production or inducing regulatory T-cell mediated tolerance.